James Burke

James currently serves as Chief Medical Officer and is responsible for clinical development at CG Oncology. James was previously CMO at Turnstone Biologics and Jennerex Biotherapeutics / SillaJen. As CMO, he oversaw oversaw global clinical development for oncolytic virus therapies from first-in-human Phase 1 to global Phase 3 studies across diverse solid tumor indications and gene therapy programs. James has over 15 years of preclinical and clinical experience in the field of gene and immunotherapy including work with various oncolytic virus platforms, tumor vaccines, and other gene therapy related agents. Prior to Jennerex, he was Associate Director of Clinical Research at Cell Genesys and was Director of Clinical Research at a regional cancer center. James earned a BS in Biochemistry from University of California, San Diego and an MD from Georgetown University. He completed a general internal medicine residency at University of California, San Diego followed by a Hematology-Oncology Fellowship at University of California, San Francisco.​